| Therapeutic Area |
Condition |
Description |
|
Haematology and Thrombosis
|
Hemophilia A |
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. |
Learn More |
|
Hemophilia B |
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B |
Learn More |
|
Hemophilia A & B |
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors |
Terminated |
|
Congenital Fibrinogen Deficiency |
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency |
Completed |
|
Von Willebrand Disease |
Study of Voncento® in Subjects With Von Willebrand Disease |
Completed |
|
Reversal of acquired coagulation factor deficiency |
An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding |
Learn More |
| Cardiovascular and Metabolic |
Acute Coronary Syndrome |
Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) |
Learn More |
| |
Coronary Heart Disease |
Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults |
Completed |
| Immunology and Neurology |
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Results |
| |
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) |
Learn More |
| |
Pediatric CIDP |
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP |
Learn More |
| |
Hereditary Angioedema (HAE) |
A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) |
Learn More |
| |
Primary Immune Deficiency (PID) |
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) |
Completed |
|
Primary Immune Deficiency (PID) |
Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules |
Results |
| |
Primary Immune Deficiency (PID) |
Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump |
Learn More |
| |
Healthy Subjects |
Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults |
Learn More |
|
Healthy Subjects |
Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults |
Completed |
| Transplant |
Antibody-mediated kidney transplant rejection |
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients |
Learn More |
| |
Acute GVHD (aGVHD) |
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) |
Learn More |
